Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Rumors are flying that Paris-based Sanofi has a $50 billion budget for mergers and acquisitions and is taking a look at U.S.-based biotech companies. At the top of the list, reportedly, is South San Francisco-based Principia Biopharma.
Unum Therapeutics announced on Monday that it has successfully completed its acquisition of Kiq LLC, a privately held biotechnology company with a focus on the discovery and development of precision kinase inhibitors.
Specifically, the report indicated that biotechnology companies drove the healthcare industry to make up almost two-thirds of IPO activity in the second quarter of 2020.
Relay Therapeutics was the No. 3 company in BioSpace’s NextGen Bio Class of 2018, Top 20 Life Science Startups to Watch in 2018.
Today, Gilead announced that it was acquiring a 49.9% equity interest in Pionyr Immunotherapeutics for $275 million and exclusive option to buy the rest of the company.
The company is focused on developing cell and gene therapies based on a proprietary DNA modification, gene editing and delivery technology.
BioSpace takes a look at some of the most recent IPO plans from companies across the globe.
Under terms of the deal, Novo Nordisk paid $725 million upfront to Sofinnova for the Waltham, Mass.-based Corvidia, a company focused on the development of transformational therapies for cardio-renal diseases.
Philadelphia, PA – Oncoceutics announced a Brown University award of $3.4 million that will be used to support a group of research teams for preclinical research, IND-enabling studies and a first-in-human clinical trial for Oncoceutics’ imipridone ONC212.
In a regulatory filing, Royalty Pharma indicated plans to offer 70 million shares of stock at a target price range of $25 to $28 per share, which would result in raising up to $1.96 billion for its initial public offering.